Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.44 |
| ▸ | NMT1 | P30419 | 4/20 | 0.41 |
| ▸ | NMT2 | O60551 | 3/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468804 | 0.87 | NAA50 (0.36) | ACENMT1NMT2APLNR | |
| SCHEMBL29411115 | 0.87 | ACE (0.49) | ACENTMT1APLNR | |
| SCHEMBL31468806 | 0.83 | APLNR (0.44) | NTMT1APLNR | |
| SCHEMBL29689651 | 0.83 | APLNR (0.44) | ACENTMT1APLNR | |
| SCHEMBL29589474 | 0.83 | ACE (0.46) | ACEFAPNTMT1APLNR | |
| SCHEMBL30905703 | 0.83 | ACE (0.44) | ACE | |
| SCHEMBL30918789 | 0.82 | OPRM1 (0.46) | ACENMT1NMT2NTMT1APLNR | |
| SCHEMBL31593256 | 0.81 | ACE (0.42) | ACEFAP | |
| SCHEMBL29363178 | 0.81 | ACE (0.59) | ACE | |
| SCHEMBL29411136 | 0.81 | ACE (0.46) | ACENTMT1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | ACE 2907/4885NMT1 441/4885NMT2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.